← Back to all trials
Not Yet Recruiting
NCT05630989
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
Conditions: Pancreatic Ductal Adenocarcinoma
Sex: All
Ages: 18 Years – N/A
Enrollment: 40
Sponsor: Mandana Kamgar, MD
Summary
This is an observational precision oncology study designed to collect and analyze data that allows us to characterize the safety and efficacy of several different mitogen-activated protein kinase kinase inhibitor (MEKi) -based treatment strategies and the feasibility of administering MEKi combination therapies to patients with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma (PDAC).
Eligibility Criteria
Inclusion Criteria:Age ≥18 years.Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board.Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician.Ability to understand a written informed consent document and the willingness to sign it.Exclusion Criteria:Age <18 years.Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinomaTumor does not have a KRAS G12R mutation.
Source: ClinicalTrials.gov (NCT05630989). StuddyBuddy aggregates publicly available trial information.
